BuyCancerDrugs.com BuyCancerDrugs.com
BuyCancerDrugs.com BuyCancerDrugs.com
OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer
Search OncologyJournal.org
Browse by Cancer Type or Cancer Drug

Go Back   OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer > Blogs > admin
Connect with Facebook


Capecitabine
Old

Health Canada Approves Trastuzumab for HER2-Positive Advanced Stomach Cancer

Posted 08-10-2010 at 02:02 PM by admin
MISSISSAUGA, Ontario -- August 9, 2010 -- After priority review, Health Canada has approved trastuzumab (Herceptin), in combination with capecitabine (Xeloda) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastroesophageal cancer.

The approval is based on the results from the international ToGA trial, which showed that trastuzumab significantly...
Administrator
Comments 0 admin is offline
Old

Data do not support sunitinib/capecitabine combo for advanced breast cancer

Posted 06-10-2010 at 05:53 PM by admin
Posted June 10, 2010

ASCO 2010 Annual Meeting

CHICAGO — A phase 3 clinical trial failed to demonstrate the superiority of treatment using sunitinib plus capecitabine compared with capecitabine alone for patients with previously treated advanced breast cancer.

John Crown, MD, consultant medical oncologist at St Vincent’s Hospital in Dublin, presented data from the trial, which sought to investigate the antiangiogenic agent, sunitinib (Sutent, Pfizer), in combination...
Administrator
Comments 0 admin is offline
Old

New agents impr. survival time at high cost in metastatic colorectal cancer patients

Posted 05-06-2010 at 08:28 PM by admin
New agents improve survival time at high cost in metastatic colorectal cancer patients

HemOnc today
Posted May 6, 2010

New chemotherapeutic agents used to treat metastatic colorectal cancer were shown to have high costs associated with their survival benefits, although the costs fell below common estimates of willingness-to-pay amounts for a life-year.

Between 1996 and 2004, several chemotherapy agents were approved to treat patients with metastatic...
Administrator
Comments 0 admin is offline
Old

Genta’s Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer

Posted 04-08-2010 at 03:58 PM by admin
April 06, 2010 08:05 AM Eastern Daylight Time

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA.OB) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for “Fast Track” designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

Fast Track designation is designed to facilitate...
Administrator
Comments 0 admin is offline
Old

AEZS: Perifosine Rec. FDA Fast Track Design. for Treatment of R.A. Colorectal Cancer

Posted 04-07-2010 at 07:16 PM by admin
Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for the Treatment of Refractory Advanced Colorectal Cancer

QUEBEC CITY, April 5 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals ( KERX), was granted Fast Track designation by the U.S. Food and Drug Administration ("FDA")...
Administrator
Comments 0 admin is offline


All times are GMT. The time now is 02:14 PM.


Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.